PubMed · 11761550
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
2000. Chlamydia: the silent STD.. https://pubmed.ncbi.nlm.nih.gov/11761550/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
A novel quantitative real-time PCR method using the duplex scorpion primer for detection of Chlamydia trachomatis DNA was developed and validated. The assay employs a duplex primer; its most important feature is the intramolecular probe-target interaction. The assay had many prominent characteristics. (i) The duplex probe is simpler to synthesize and significantly easier to purify than TaqMan probe because that the fluorescent dye pair and the quencher pair are in different oligonucleotides. (ii) The method has high sensitivity, specificity, intra- and interassay reproducibilities. (iii) The assay has a quantitative dynamic range of 25 to10(9) genome copies per reaction mixture. (iv) The scorpion system can identify 98.6% samples in the validation panel without retest. There were 81 positive samples and 67 negative samples, which were confirmed by two FDA-approved NAATs (the Roche Amplicor PCR assay, Abbott LCR kit) and our new method. Any two positive results out of the possible three-comparator results would define the infected-patient gold standard. Of the positive samples, 79 (97.5%) were found positive (ranging from 31 to 227,648 copies/microl, M=4219 copies/microl), whereas no negative samples were found positive by the assay. A quantitative, fast, and easy-to-handle diagnostic approach such as the MOMP-based real-time PCR described here might improve the detection of C. trachomatis infection.
Genital chlamydia infections are the most frequently diagnosed bacterial sexually transmitted infection (STI) worldwide. Infections with chlamydia trachomatis are not notifiable in Germany. Since 2002, a STI sentinel surveillance including 243 sentinel sites has been set up in Germany. Between January 2003 and June 2006, 6.7% of 46,168 chlamydia tests were positive. Of the 1547 positive patients, 64.3% were women and the median age was 26 years. In this group, 60.4% of women and 29.3% of men were of non-German origin. Heterosexual contacts were stated as the possible source of infection for 42.9% of men and 26.4% of women. A total of 16.1% men and 38.6% women reportedly "always" used condoms with others than their permanent partner. The awareness of chlamydia infections needs to be improved among physicians, patients and the general population.
Genital infections with Chlamydia trachomatis occur in all social groups in Germany. About 100,000 German women are sterile because of tubal scarring due to chlamydiae. Genital chlamydial infections are asymptomatic in 70% of patients, even if salpingitis occurs. Typical symptoms of chlamydial infection are purulent cervicitis with vaginal discharge, painful cervical bleeding because of endometritis, lower abdominal pain with dyspareunia, and upper abdominal pain because of perihepatitis. DNA amplification tests on first voided urine or cervical swab are the most sensitive routine tests. Specific serum antibodies to C. trachomatis indicate a previous infection in sterile women. For treatment, a 10-14 day course of doxycycline 200 mg daily or a macrolide antibiotic in the patient as well as in the sexual partner is recommended. In the male, C. trachomatis causes urethritis and epididymitis. Opinions differ about involvement of the prostate gland and seminal vesicles. Identification of C. trachomatis antigen or DNA in the accessory gland secretions is not sufficiently reproducible. The two vectors are easily diagnosed in urethral swabs or in urine. The occurrence of chlamydial antibodies in serum or in seminal fluid is not a sign of current infection. Reliable studies which indicate a reduced fertility of men infected with C. trachomatis are not available.